Suven Life Sciences receives product patents in Australia and Europe
Suven Life Sciences informed the bourses that it has received the grant of the product patents from Australia, Eurasia and Europe corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2034.
In April 2018, the company had secured product patent from Canada. With the grant of these patents, the company’s pipeline of molecules will be further developed for cognitive disorders to cater to a huge unmet medical need present in the global market.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products.
On Wednesday, the stock opened at Rs. 184.60 and touched an intra-day high and low of Rs. 187.60 and Rs. 182.35, respectively, on the BSE.